Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Gary Lyons

Affiliations

  • Director at Novus Therapeutics Inc. (NVUS), 2019-07-15
  • Director at Rigel Pharmaceuticals Inc (RIGL), 2019-05-24
  • Director at Neurocrine Biosciences Inc (NBIX), 2019-05-23
  • Director at Retrophin Inc. (RTRX), 2019-05-11
  • Director at Vical Inc (VICL), 2018-05-24
  • Director at Cytori Therapeutics Inc. (CTYX), 2018-02-09
  • Director at Kalobios Pharmaceuticals Inc (KBIO), 2015-07-14
  • Director at Neurogesx Inc (NGSX), 2012-06-12
  • Director at Poniard Pharmaceuticals Inc. (PARD), 2011-07-12
  • Director at Facet Biotech Corp (FACT), 2010-04-23
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
VICL $4.39 7,078 Director 14,906 2016-06-03 Filing
VICL $0.01 5,953 Director 63,281 2013-05-23 Filing
VICL $0.01 7,328 Director 57,328 2012-05-24 Filing
VICL $0.01 18,750 Director 50,000 2011-05-26 Filing
VICL $0.01 18,750 Director 31,250 2010-05-25 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
NBIX $114.41 15,000 Director 245,697 2018-11-02 Filing
NBIX $99.24 15,000 Director 260,697 2018-06-13 Filing
NBIX $84.67 5,000 Director 262,066 2018-02-15 Filing
NBIX $83.08 5,000 Director 267,066 2018-02-05 Filing
NBIX $72.92 10,000 Director 272,066 2017-12-01 Filing